Experience with gemcitabine-carboplatine chemotherapy in relapsed ovarian cancer;Kiújult petefészekrákok gemcitabin-carboplatin kezelésével szerzett tapasztalataink

Orvosi Hetilap

Volumn 147, Issue 30, 2006, Pages 1405-1408

  Lehoczky, Ottó ^a,b   Pulay, Tamás ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NONE   (Hungary)

Author keywords

Chemotherapy; Gemcitabine; Progression free interval; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; GEMCITABINE; LITHIUM CARBONATE; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER PROGRAM; DISEASE FREE INTERVAL; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; OUTCOME ASSESSMENT; OVARY CANCER; RECURRENT CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33749339374     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Általános Toxicitási Jellemzok. www.slz.n1/hora /protocol/ appendices/whotoxic.htm. (letöltés ideje 2005. május 10.)
2. Bilgin, T, Özalp, S., Yalcin, Ö. T. és mtsai: Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur. J. Gynaec. Oncol., 2003, 24, 169-170.
3. D'Agostino, G., Amant, R, Berteloot, P. és mtsai: Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol. Oncol., 2003, 88, 266-269.
4. du Bois, A., Luck, H. J., Pfisterer, J. és mtsai: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer. A dose finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol., 2001, 12, 1115-1120.
5. Francis, P., Schneider, J., Hann, L. és mtsai: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol. 1994, 12, 2301-2308.
6. Israel, V. P., Garcia, A. A., Roman, L. és mtsai: Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol. Oncol. 2000, 78, 143-147.
7. Kose, M, F, Sufliarsky, J., Beslija, S. és mtsai: A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol. Oncol., 2005, 96, 374-380.
8. Lehoczky O., Bagameri A., Udvary J. és mtsa: Kiújult petefészekrákok második vonalú paclitaxel kezelése. Orv. Hetil., 2001, 142, 2299-301.
9. Lehoczky O.: A gemcitabin kezelés eredményessége az irodalmi adatok tükrében. Orv. Hetil., 2005, 146, 2351-2357.
10. Lund, B., Hansen, O. P., Theilade, K. és mtsai: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst., 1994, 86, 1530-1533.
11. McGuire, W. P., Hoskins, W. J., Brady, M. F. és mtsai: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 1996, 334, 1-6.
12. Mutch, D. G.: Gemcitabine combination chemotherapy of ovarian cancer. Gynecol. Oncol., 2003, 90, S16-20.
13. Nagourney, R. A., Brewer, C. A., Radecki, S. és mtsai: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol., 2003, 88, 35-39.
14. Papadimitriou, C. A., Fountzilas, G., Aravantinos, G. és mtsai: Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol. Oncol., 2004, 92, 152-159.
15. Parmar, M. K., Ledermann, J. A., Colombo, N. és mtsai: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003, 361, 2099-2106.
16. Peters, G. J., Bergman, A. M., Ruiz van Haperen, V. W. és mtsai: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol., 1995, 4 (Suppl. 11.), 72-79.
17. Pfisterer, J., Vergote, I., Du Bois, A. és mtsa: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer, 2005, 15 (Suppl. 1.), 36-41.
18. Rose, P. G., Blessing, J. A., Mayer, A. R. és mtsa: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol., 1998, 16, 405-410.
19. Rose, P. G., Mossbruger, K., Fusco, N. és mtsai: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol., 2003, 88, 17-21.
20. ten Bokkel Huinink, W., Gore, M., Carmichael, J. és mtsai: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 1997, 15, 2183-2193.
21. Tewari, D., Monk, B. J., Hunter, M. és mtsai: Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest. New Drugs, 2004, 22, 475-480.